S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:OPGN

OpGen - OPGN Stock Forecast, Price & News

$0.13
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.13
$0.14
50-Day Range
$0.14
$0.38
52-Week Range
$0.13
$1.47
Volume
348,843 shs
Average Volume
371,729 shs
Market Capitalization
$6.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13

OpGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,533.4% Upside
$2.13 Price Target
Short Interest
Healthy
0.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

OPGN stock logo

About OpGen (NASDAQ:OPGN) Stock

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock News Headlines

OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com
Form 424B5 OPGEN INC - StreetInsider.com
OpGen Announces $3.38 Million Registered Direct Offering
See More Headlines
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Company Calendar

Last Earnings
11/11/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPGN
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.13
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+1,533.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-34,810,000.00
Net Margins
-1,016.12%
Pretax Margin
-1,011.93%

Debt

Sales & Book Value

Annual Sales
$4.31 million
Book Value
$1.06 per share

Miscellaneous

Free Float
52,765,000
Market Cap
$6.99 million
Optionable
Not Optionable
Beta
-0.22

Key Executives

  • Dr. Oliver Schacht Ph.D. (Age 51)
    CEO, Pres & Director
    Comp: $600.2k
  • Mr. Johannes  BacherMr. Johannes Bacher (Age 53)
    Chief Operating Officer
    Comp: $396.52k
  • Mr. Albert Weber (Age 59)
    CFO & Corp. Sec.
  • Mr. Vadim Sapiro (Age 51)
    Chief Information Officer
  • Mr. Michael Farmer
    VP of Marketing
  • Ms. Faranak Atrzadeh
    Chief Marketing & Scientific Affairs Officer
  • Dr. G. Terrance Walker Ph.D. (Age 63)
    Sr. VP of R&D
  • Mr. Derek Joesting
    Sr. VP of US Sales
  • Dr. Arne Materna
    MD & CEO of Ares Genetics GmbH













OPGN Stock - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPGN shares.
View OPGN analyst ratings
or view top-rated stocks.

What is OpGen's stock price forecast for 2023?

2 Wall Street research analysts have issued 1-year target prices for OpGen's shares. Their OPGN share price forecasts range from $1.25 to $3.00. On average, they predict the company's share price to reach $2.13 in the next twelve months. This suggests a possible upside of 1,533.4% from the stock's current price.
View analysts price targets for OPGN
or view top-rated stocks among Wall Street analysts.

How have OPGN shares performed in 2022?

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 87.0% and is now trading at $0.1301.
View the best growth stocks for 2022 here
.

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our OPGN earnings forecast
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its quarterly earnings data on Thursday, November, 11th. The medical research company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The medical research company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $1.20 million. OpGen had a negative trailing twelve-month return on equity of 91.83% and a negative net margin of 1,016.12%. During the same period in the previous year, the business posted ($0.40) earnings per share.

When did OpGen's stock split?

Shares of OpGen reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.50 million-$3.00 million, compared to the consensus revenue estimate of $4.51 million.

What other stocks do shareholders of OpGen own?
When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.87%), Vanguard Group Inc. (3.50%), Renaissance Technologies LLC (0.22%) and Citadel Advisors LLC (0.19%). Insiders that own company stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends
.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $0.13.

How much money does OpGen make?

OpGen (NASDAQ:OPGN) has a market capitalization of $6.99 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for the company is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.

This page (NASDAQ:OPGN) was last updated on 12/8/2022 by MarketBeat.com Staff